For a very a long time, scientists and medical researchers have been scouting for therapeutic alternatives to relapsing-remitting multiple sclerosis (or MS), an autoimmune condition in which the patient’s immune system attacks his or her central nervous system. However, results from a recent clinical trial has rekindled their hopes: it has provided evidence that HDIT (or high-dose immunosuppressive therapy coupled with subsequent autologous hematopoietic cell transplant (or transplantation of the patient’s blood-forming stem cells) could induce long term remission of relapsing-remitting MS.
Because HDIT will be a one-time treatment, it could be more effective than the current long-term treatment options for relapsing-remitting MS patients. The new National Institute of Allergy and Infectious Diseases’ sponsored study findings, therefore, support the development of bigger, randomized trials to compare the effectiveness of HDIT/HCT treatment to the standard care that relapsing-remitting MS patients are currently receiving.
Although an in-depth evaluation of full benefits as well as the potential risk of this treatment option is still needed, the new study results is a great step towards finding sustained remissions of ineffective prognosis of relapsing-emitting MS.
In case the new findings are proved and confirmed in larger studies, HDIT/HCT may become the new therapeutic treatment option for active relapsing-emitting MS patients, especially those who aren’t responding well to existing therapies. This is one of the primary reasons why many medical experts and stakeholders are keenly following the new study and any information related to it. One of these experts is the Voorhees-based Shiva Gopal Vasishta.
Shiva Gopal Vasishta is a practicing Neurologist with over 4 decades of experience. A graduate of the Government Medical College (1979), Dr. Shiva Vasishta is also a psychiatry specialist. Currently, Dr. Shiva Vasishta practices at the prestigious Eastern Neurodiagnostic Associates. He’s also affiliated to Cherry Hill Campus’ Kennedy Health System.